Antitumor activity of PEGylated biodegradable nanoparticles for sustained release of docetaxel in triple-negative breast cancer

Giuseppe Palma, Claudia Conte, Antonio Barbieri, Sabrina Bimonte, Antonio Luciano, Domenica Rea, Francesca Ungaro, Pasquale Tirino, Fabiana Quaglia, Claudio Arra

Research output: Contribution to journalArticlepeer-review

Abstract

With the aim to find novel therapeutical approaches for triple-negative breast cancer (TNBC) treatment, we have developed a powder for i.v. injection based on cyclodextrins and docetaxel (DTX)-loaded polyethyleneglycol- poly(epsilon-caprolactone) nanoparticles (DTX-NPs). Nanoparticles are designed to concentrate at tumor level by enhanced permeability and retention effect and release drug cargo at a sustained rate in the blood and in tumor interstitium. DTX-NPs of around 70 nm, shielding proteins and allowing a sustained DTX release for about 30 days, were produced by melting sonication technique. DTX-NPs were associated to hydroxypropyl-β-cyclodextrin to give a powder for injection with excellent dispersibility and suitable for i.v. administration. DTX-NPs were as efficient as free DTX in inhibiting cell growth of MDA-MB231 cells, even at low concentrations, and displayed a comparable in vivo antitumor efficacy and better survival in a TNBC animal model as compared with DTX commercial formulation (Taxotere®). In conclusion, PEGylated biodegradable DTX-NPs highlighted their potential in the treatment of aggressive TNBC providing a foundation for future clinical studies.

Original languageEnglish
Pages (from-to)55-63
Number of pages9
JournalInternational Journal of Pharmaceutics
Volume473
Issue number1-2
DOIs
Publication statusPublished - Oct 1 2014

Keywords

  • Docetaxel
  • PEGylated nanoparticles
  • Powder for injection
  • Sustained release
  • Triple-negative breast cancer

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Medicine(all)

Fingerprint Dive into the research topics of 'Antitumor activity of PEGylated biodegradable nanoparticles for sustained release of docetaxel in triple-negative breast cancer'. Together they form a unique fingerprint.

Cite this